Clinical Trials
3 trialsNCT02971501 2026-05-29
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07491211 2026-03-27
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
Fudan University
Active not recruiting
NCT07206498 2025-11-28
WAYWIN103
Wayshine Biopharm, Inc.
Phase 1/2 Recruiting